Pharmacokinetics of indium-111 BLEDTA in man

D. J. Sartoris, D. A. Goodwin, C. F. Meares, L. H. DeRiemer, L. F. Fajardo

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

111In-BLEDTA is a bleomycin-containing radiopharmaceutical that has proven useful as a tumor imaging agent. Whole blood distribution and pharmacokinetic parameters were studied in nine cancer patients, and the results compared with previously reported studies using 57Co-bleomycin. In eight patients studied by bolus intravenous injection, 111In-BLEDTA had a beta half-life (t( 1/2 β)) of 1.3 hours, a terminal-phase half-life (t( 1/2 )) of 11.7 hours, a volume of distribution (V(dγ)) of 57.5 L/m2, a total body clearance rate (C(1b2)) of 52.8 ml/min/m2, a renal clearance rate (C1(r)) of 23.3 ml/min/m2, and a 24-hour urinary excretion of 38.1% total administered dose. 111In-BLEDTA and 57Co-bleomycin have similar C1(bs) but differing V(ds). Polymorphonuclear cell uptake of 111In-BLEDTA may explain its shorter t( 1/2 β) and t( 1/2 ), as well as its lower C1(r) and 24-hour urinary excretion. While the biologic characteristics of 111In-BLEDTA contribute to a greater background activity than is observed in scans with 57Co-bleomycin, its superior physical properties render it clinically more desirable as a tumor-imaging radiopharmaceutical.

Original languageEnglish (US)
Pages (from-to)221-227
Number of pages7
JournalInvestigative Radiology
Volume19
Issue number3
StatePublished - 1984

Fingerprint

Indium
Bleomycin
Pharmacokinetics
Radiopharmaceuticals
Half-Life
Metabolic Clearance Rate
Neoplasms
Intravenous Injections
BLEDTA
Kidney

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Radiological and Ultrasound Technology

Cite this

Sartoris, D. J., Goodwin, D. A., Meares, C. F., DeRiemer, L. H., & Fajardo, L. F. (1984). Pharmacokinetics of indium-111 BLEDTA in man. Investigative Radiology, 19(3), 221-227.

Pharmacokinetics of indium-111 BLEDTA in man. / Sartoris, D. J.; Goodwin, D. A.; Meares, C. F.; DeRiemer, L. H.; Fajardo, L. F.

In: Investigative Radiology, Vol. 19, No. 3, 1984, p. 221-227.

Research output: Contribution to journalArticle

Sartoris, DJ, Goodwin, DA, Meares, CF, DeRiemer, LH & Fajardo, LF 1984, 'Pharmacokinetics of indium-111 BLEDTA in man', Investigative Radiology, vol. 19, no. 3, pp. 221-227.
Sartoris DJ, Goodwin DA, Meares CF, DeRiemer LH, Fajardo LF. Pharmacokinetics of indium-111 BLEDTA in man. Investigative Radiology. 1984;19(3):221-227.
Sartoris, D. J. ; Goodwin, D. A. ; Meares, C. F. ; DeRiemer, L. H. ; Fajardo, L. F. / Pharmacokinetics of indium-111 BLEDTA in man. In: Investigative Radiology. 1984 ; Vol. 19, No. 3. pp. 221-227.
@article{209aeae5c95a4eccbae5dc741ba687e5,
title = "Pharmacokinetics of indium-111 BLEDTA in man",
abstract = "111In-BLEDTA is a bleomycin-containing radiopharmaceutical that has proven useful as a tumor imaging agent. Whole blood distribution and pharmacokinetic parameters were studied in nine cancer patients, and the results compared with previously reported studies using 57Co-bleomycin. In eight patients studied by bolus intravenous injection, 111In-BLEDTA had a beta half-life (t( 1/2 β)) of 1.3 hours, a terminal-phase half-life (t( 1/2 )) of 11.7 hours, a volume of distribution (V(dγ)) of 57.5 L/m2, a total body clearance rate (C(1b2)) of 52.8 ml/min/m2, a renal clearance rate (C1(r)) of 23.3 ml/min/m2, and a 24-hour urinary excretion of 38.1{\%} total administered dose. 111In-BLEDTA and 57Co-bleomycin have similar C1(bs) but differing V(ds). Polymorphonuclear cell uptake of 111In-BLEDTA may explain its shorter t( 1/2 β) and t( 1/2 ), as well as its lower C1(r) and 24-hour urinary excretion. While the biologic characteristics of 111In-BLEDTA contribute to a greater background activity than is observed in scans with 57Co-bleomycin, its superior physical properties render it clinically more desirable as a tumor-imaging radiopharmaceutical.",
author = "Sartoris, {D. J.} and Goodwin, {D. A.} and Meares, {C. F.} and DeRiemer, {L. H.} and Fajardo, {L. F.}",
year = "1984",
language = "English (US)",
volume = "19",
pages = "221--227",
journal = "Investigative Radiology",
issn = "0020-9996",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Pharmacokinetics of indium-111 BLEDTA in man

AU - Sartoris, D. J.

AU - Goodwin, D. A.

AU - Meares, C. F.

AU - DeRiemer, L. H.

AU - Fajardo, L. F.

PY - 1984

Y1 - 1984

N2 - 111In-BLEDTA is a bleomycin-containing radiopharmaceutical that has proven useful as a tumor imaging agent. Whole blood distribution and pharmacokinetic parameters were studied in nine cancer patients, and the results compared with previously reported studies using 57Co-bleomycin. In eight patients studied by bolus intravenous injection, 111In-BLEDTA had a beta half-life (t( 1/2 β)) of 1.3 hours, a terminal-phase half-life (t( 1/2 )) of 11.7 hours, a volume of distribution (V(dγ)) of 57.5 L/m2, a total body clearance rate (C(1b2)) of 52.8 ml/min/m2, a renal clearance rate (C1(r)) of 23.3 ml/min/m2, and a 24-hour urinary excretion of 38.1% total administered dose. 111In-BLEDTA and 57Co-bleomycin have similar C1(bs) but differing V(ds). Polymorphonuclear cell uptake of 111In-BLEDTA may explain its shorter t( 1/2 β) and t( 1/2 ), as well as its lower C1(r) and 24-hour urinary excretion. While the biologic characteristics of 111In-BLEDTA contribute to a greater background activity than is observed in scans with 57Co-bleomycin, its superior physical properties render it clinically more desirable as a tumor-imaging radiopharmaceutical.

AB - 111In-BLEDTA is a bleomycin-containing radiopharmaceutical that has proven useful as a tumor imaging agent. Whole blood distribution and pharmacokinetic parameters were studied in nine cancer patients, and the results compared with previously reported studies using 57Co-bleomycin. In eight patients studied by bolus intravenous injection, 111In-BLEDTA had a beta half-life (t( 1/2 β)) of 1.3 hours, a terminal-phase half-life (t( 1/2 )) of 11.7 hours, a volume of distribution (V(dγ)) of 57.5 L/m2, a total body clearance rate (C(1b2)) of 52.8 ml/min/m2, a renal clearance rate (C1(r)) of 23.3 ml/min/m2, and a 24-hour urinary excretion of 38.1% total administered dose. 111In-BLEDTA and 57Co-bleomycin have similar C1(bs) but differing V(ds). Polymorphonuclear cell uptake of 111In-BLEDTA may explain its shorter t( 1/2 β) and t( 1/2 ), as well as its lower C1(r) and 24-hour urinary excretion. While the biologic characteristics of 111In-BLEDTA contribute to a greater background activity than is observed in scans with 57Co-bleomycin, its superior physical properties render it clinically more desirable as a tumor-imaging radiopharmaceutical.

UR - http://www.scopus.com/inward/record.url?scp=0021277167&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021277167&partnerID=8YFLogxK

M3 - Article

C2 - 6206021

AN - SCOPUS:0021277167

VL - 19

SP - 221

EP - 227

JO - Investigative Radiology

JF - Investigative Radiology

SN - 0020-9996

IS - 3

ER -